



**Technology Brief: Inhibitors of ROCK1 as Novel Anti-Cancer Agents**

Docket Number: 06B134

<b>Summary</b>	<ul style="list-style-type: none"><li>• ROCK1, or Rho kinase, is a protein kinase activated by Rho that plays a signaling role in cell morphology, transformation, motility, focal adhesion, and cytokinesis.</li><li>• Inhibition of this pathway may prevent tumor cell motility and metastasis.</li><li>• Novel small-molecule inhibitors of ROCK1 have been synthesized and assayed for activity in vitro, and are candidates as anti-cancer drugs.</li></ul>
<b>Features and Benefits</b>	<ul style="list-style-type: none"><li>• Novel compounds have been synthesized that exhibit strong inhibition of ROCK1, offering potentially high potency.</li><li>• The synthetic routes are short and have high yields.</li><li>• The inhibitors have improved selectivity for ROCK1 over other protein kinases, offering potential as superior targeted agents.</li></ul>
<b>Stage of Development</b>	Lead optimization.
<b>Inventors</b>	Drs. S. M. Sebti and A. D. Hamilton
<b>Patents</b>	Patent application filed

**Contact Information:**

**Haskell Adler PhD MBA**  
Senior Licensing Manager  
Email: [haskell.adler@moffitt.org](mailto:haskell.adler@moffitt.org)  
Telephone: 813-745-6596

**H. Lee Moffitt Cancer Center and Research Institute, Inc.**  
Office of Technology Management and Commercialization  
12902 Magnolia Drive MRC-TTO  
Tampa, FL 33612  
Website: <http://www.moffitt.org/OTMC>